Sunshine Biopharma, Inc. (SBFM)
NasdaqCM
Price as at 1 Oct 2026, 00:56 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Sunshine Biopharma, Inc. trades at $0.77. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Sunshine Biopharma, Inc.
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its SBFM data?
Fundamentals for SBFM come from company filings and exchange data, as listed on NasdaqCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 00:56 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for SBFM, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.